Susquehanna International Group, LLP Eliem Therapeutics, Inc. Transaction History
Susquehanna International Group, LLP
- $568 Billion
- Q1 2025
A detailed history of Susquehanna International Group, LLP transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 42,506 shares of ELYM stock, worth $174,699. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,506
Previous 14,246
198.37%
Holding current value
$174,699
Previous $58,000
200.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ELYM
# of Institutions
72Shares Held
49.8MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.68% of portfolio
-
Cantor Fitzgerald, L. P. New York, NY2MShares$8.22 Million0.18% of portfolio
-
Citigroup Inc1.85MShares$7.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.5MShares$6.18 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.5MShares$6.17 Million0.69% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...